JB Reed/BloombergTablets of the generic antipsychotic drug Risperidone, used to treat schizophrenia, are arranged for a photo at a pharmacy in New York, U.S., on Wednesday, March 2, 2011. Johnson & Johnson's antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments like the generic Risperidone at keeping schizophrenia patients out of the hospital, U.S. researchers said.

Johnson & Johnson settled a lawsuit on the first day of a trial over claims by a male plaintiff that its antipsychotic drug Risperdal caused him to grow breast tissue, it was announced in court in Philadelphia.

Aron Banks, 21, claimed he sustained psychological trauma from growing breasts after taking the medication during childhood. Banks took the medicine from 2000 to 2004, when it wasn’t approved for children.

The Banks suit in state court in Philadelphia was the first to go to trial on claims that Risperdal caused boys to grow breasts. Another trial is set to begin Sept. 20 in Philadelphia. The terms of the settlement are confidential, Steve Sheller, the plaintiff’s attorney, said following the announcement in court today.

“The case resolved and the client is satisfied,” Sheller said in an interview.

The Food and Drug Administration approved Risperdal in 1993 for psychotic disorders including schizophrenia. It was later approved for other uses. Johnson& Johnson is based in New Brunswick, New Jersey.